Olon has begun construction of a new GMP manufacturing facility at its microbial CDMO facility in Capua, Italy. The Active Pharmaceutical Ingredients (API) CDMO and generics supplier has 11 manufacturing facilities spread over Europe (Italy and Spain), the US (Concord OH) and India (Mahad).
The construction of this new GMP facility is associated with a long-term strategic partnership with a large pharmaceutical company.
The engineering project is designed to support the manufacture of multiple products, up to commercial scale. This project comes after Olon's recent undertakings in the development and execution of GMP as well as food-grade engineering projects; from first concept to final commissioning, based on green-field and brown-field, under challenged timelines.
Paolo Tubertini, CEO of Italy-based Olon, said: "I am pleased to announce the start of this GMP capacity expansion just 6 months after the acquisition of Capua BioServices. This truly confirms the real opportunity to accelerate growth in Olon's CDMO service positioning and to be recognised as European Leader in the CDMO of microbial fermentation."